Immunotherapy Approaches for Breast Cancer Patients in 2023
- Details
- Publication Year 2023-04-03,Volume 13,Issue #4,Page a041332
- Journal Title
- Cold Spring Harbor Perspectives in Medicine
- Publication Type
- Review
- Abstract
- Immunotherapy, particularly agents targeting the immunoregulatory PD-1/PD-L1 axis, harnesses the power of the immune system to treat cancer, with unique potential for a durable treatment effect due to immunologic memory. The PD-1 inhibitor pembrolizumab combined with neoadjuvant chemotherapy followed by adjuvant pembrolizumab improves event-free survival and is a new standard of care for high-risk, early-stage triple-negative breast cancer (TNBC), regardless of tumor PD-L1 expression. For metastatic TNBC, pembrolizumab combined with chemotherapy is a new standard of care for the first-line therapy of PD-L1(+) metastatic TNBC, with improvement in overall survival. The PD-L1 inhibitor atezolizumab combined with nab-paclitaxel is also approved outside the United States for the first-line treatment of metastatic PD-L1(+) TNBC. Current research focuses on refining the use of immunotherapy in TNBC by defining informative predictive biomarkers, developing immunotherapy in early and advanced HER2-driven and luminal breast cancers, and overcoming primary and secondary resistance to immunotherapy through unique immune-based strategies.
- Publisher
- Cold Spring Harbor Laboratory Press
- Keywords
- Humans; *Triple Negative Breast Neoplasms/drug therapy/metabolism; B7-H1 Antigen/therapeutic use; Biomarkers; Immunotherapy; Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Department(s)
- Medical Oncology
- PubMed ID
- 37011999
- Publisher's Version
- https://doi.org/10.1101/cshperspect.a041332
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2023-07-19 07:47:31
Last Modified: 2023-07-19 07:47:59